Papillary thyroid carcinoma (PTC) is associated with RET and NTRK1 rearrangements and BRAF mutations. A series of 60 PTCs collected in a single center from Italian patients were histologically re-examined and subclassified as well differentiated or tall cell variant. The sample collection was analysed for the presence of all the reported PTCassociated genetic alterations through DNA or cDNA amplification, followed by automated sequencing. The analysis of exons 11 and 15 of BRAF gene revealed the T1796A (V599E) mutation in 32% of cases, and this alteration is significantly associated with PTC tall cell variant. Oncogenic rearrangements of RET and NTRK1 receptors were found in 33 and 5% of cases, respectively. No Ras mutations were detected. Overall, genetic alterations were detected in two-thirds of samples, and in no single case more than one mutational event was found simultaneously. Gene expression profiling of a subset of 31 tumors performed using cDNA microarray chips showed no strong differences in global gene expression among the different cases. However, a supervised analysis of the obtained data identified a subset of genes differentially expressed in tumors carrying BRAF mutation or RTK rearrangement.
A broad spectrum of tumors with different phenotypic, biological and clinical features originates from the epithelial follicular cells. Their behavior varies from the indolent growing, well-differentiated papillary and follicular carcinomas (PTC and FTC) , to the extremely aggressive anaplastic carcinoma (Sherman, 2003) .
A number of findings suggest that distinct molecular events are associated with specific histotypes, together with a good genotype/phenotype correlation (Pierotti et al., 1996) . FTC is characterized by the occurrence of the t(2;3) (q13;p25) translocation, which produces the PAX8/PPARg fusion gene, and by activating mutations of Ras genes (Sherman, 2003) . PTC represents the most frequent malignant tumor of the thyroid gland, accounting for about 80% of all thyroid cancers, and including several different histological variants (Sherman, 2003) . A variable portion of PTC is associated with chromosomal rearrangements producing chimeric oncogenes containing the tyrosine kinase (TK) domain of RET and NTRK1 receptors (Pierotti et al., 1996) . RET/PTC oncogenes represent the most frequent alteration in PTC, although wide variations of frequency, ranging from 5 to 70%, have been observed among different geographic areas (Jhiang, 2000) . The occurrence of Ras gene mutations in PTC is controversial, since some authors found the latter at various frequencies, whereas other studies did not identify any mutation (Esapa et al., 1999) . Differences in methodology and histological classification may explain discrepant results. Recently, a somatic point mutation in the BRAF gene has been identified as the most common genetic lesion in PTC (Cohen et al., 2003; Fukushima et al., 2003; Kimura et al., 2003; Namba et al., 2003; Nikiforova et al., 2003; Soares et al., 2003; Xu et al., 2003) . In different series of PTC, the V599E mutation, increasing the basal kinase activity of BRAF (Davies et al., 2002) , has been detected, with frequency ranging from 29 to 69% (Cohen et al., 2003; Fukushima et al., 2003; Kimura et al., 2003; Namba et al., 2003; Nikiforova et al., 2003; Soares et al., 2003; Xu et al., 2003) . The cooperation between BRAF mutation and RET/PTC oncogene activation in the pathogenesis of PTC is debated. Soares et al. (2003) and Kimura et al. (2003) proposed the two events as alternative, whereas Xu et al. (2003) suggested that BRAF mutation may cooperate with RET/PTC in the oncogenesis of PTC.
With the intent of limiting the variability of different case sets subjected to diverse histopathological interpretations, we have analysed in a series of PTCs collected in a single center, the Istituto Nazionale Tumori (Milan, Italy), the presence of all the so far reported PTC-associated genetic alterations. This also included NTRK1 rearrangement, a specific, although not very frequent, PTC lesion. Moreover, a gene expression analysis of a subset of these cases was also performed.
The PTC collection was histologically re-examined, in a blinded manner, by two experienced pathologists, and subclassified as well-differentiated (n ¼ 46) or tall cell variant (n ¼ 14), according to previous reported criteria (Pilotti et al., 1995) . The sample collection was analysed for the presence of all the reported PTC-associated genetic alterations. The occurrence of BRAF mutations was investigated in exons 11 and 15, since all the reported BRAF mutations fall within these latter (Davies et al., 2002) . In 19 out 60 samples (31.7%), we detected the thymine-to-adenine transversion at nucleotide 1796, which results in the valine-to-glutamate substitution at residue 599 (V599E). Nucleotide 1796 is the most frequently affected hot-spot in human cancers where BRAF is mutated (Davies et al., 2002) and the only mutational site in PTC (Cohen et al., 2003; Fukushima et al., 2003; Kimura et al., 2003; Namba et al., 2003; Nikiforova et al., 2003; Soares et al., 2003; Xu et al., 2003) . The V599E mutation leads to an increase of BRAF basal kinase activity, resulting in a constitutive activation of the BRAF/MAP kinases pathway (Davies et al., 2002) . In two samples, we have also found two other BRAF mutations: a G to A transition at nucleotide 1365 in exon 11, without aminoacid change, and a G to A transition in intron 11. In both cases any effect of such mutations on BRAF activity seems unlikely, and the cases were classified as BRAF negative.
As mentioned previously, the occurrence of Ras genes mutations in PTC is still debated: some authors have reported their prevalence varying between 6 and 45%, whereas other studies have failed to identify them (Esapa et al., 1999) . In our case material no N-Ras and K-Ras mutations were detected; H-Ras point mutations at codon 12, 13 or 61 were not identified, except for a known, silent polymorphism (CAT to CAC) at codon 27 detected in about half of the cases. Thus, no tumors of our collection showed Ras activating mutations. These results are in agreement with a previous study performed by our group on a different thyroid carcinoma collection and using a different methodology (Manenti et al., 1994) , and demonstrate that Ras mutations are absent or infrequent in PTC. The conflicting data on the prevalence of Ras mutation in PTC might be explained by ethnic differences, different classification criteria, rather than different methodologies.
The sample collection was characterized for the presence of RET and NTRK1 rearrangements by RT-PCR. In some instances, the oncogenic rearrangements, leading to the activation of these oncogenes, were reconfirmed by DNA transfection/focus formation assay (data not shown). On the whole, the analysis of RET and NTRK1 rearrangements was performed on 55 cases since for the five remaining samples no frozen material was available. The analysis for RET rearrangements was performed by RT-PCR designed to detect unequivocally RET oncogenes and distinguish them from RET wild-type expression (Klugbauer et al., 1995) . RET rearrangement was detected in 18 out 55 cases (32.7%). Amplification with primers specific for the most frequent RET/PTC oncogene types identified PTC1 in 10 cases, PTC2 in two cases and PTC3 in six cases. Interestingly, a consistent fraction (27%, data not shown) of PTCs showed expression of the wildtype RET receptor mRNA, with no evidence of rearrangement. This finding is in agreement with a previous report, suggesting that RET expression may play a role in follicular thyroid cells (Bunone et al., 2000) . As far as NTRK1 gene rearrangement is concerned, the analysis was performed by RT-PCR. Expression of NTRK1 TK domain, which is suggestive of oncogenic rearrangement, was found in three out 55 cases (5.5%). The specific oncogenes were subsequently identified: TRK in two cases and TRK-T1 in one case (Pierotti et al., 1996) .
Our analysis took into consideration all the so far reported PTC-associated genetic lesions, including NTRK1 rearrangement. At odds with Xu et al. (2003) and in keeping with Soares et al. (2003) and Kimura et al. (2003) , our analysis, performed by RT-PCR designed to detect unequivocally RET rearrangements, and to distinguish them from RET wild-type expression, clearly indicates the lack of overlapping among the PTC-associated genetic lesions investigated. Indeed, in no single case more than one mutational event was found simultaneously (Table 1) . It is worth mentioning that in the study of Xu et al. (2003) RET rearrangement was deduced simply by immunohistochemical analysis using carboxy-terminal-specific antibodies (Xu et al., 2003) , which are unable to discriminate between the wild-type and the rearranged RET. The positivity for RET protein expression in that study might be explained by the wild-type receptor expression without the presence of RET oncogene (Bunone et al., 2000) .
Contrary to RET rearrangements, whose frequency, as indicated previously, is widely different depending on the series examined (Jhiang, 2000) , the frequency of BRAF mutation detected in our case material is comparable to that observed in sample collection from different geographic areas (Cohen et al., 2003; Fukushima et al., 2003; Kimura et al., 2003; Namba et al., 2003; Nikiforova et al., 2003; Soares et al., 2003; Xu et al., 2003) . A sporadic significant association between BRAF mutation and clinical-pathological parameters (such as age, stage and distant metastasis) has been reported (Namba et al., 2003; Xu et al., 2003) . In our study, no significant association between BRAF mutation and the various clinical-pathological features was detected (data not shown), except for PTC variants. As reported in Table 2 , BRAF mutation segregates (Po0.001) with tall cell variant, where we detected a low frequency (9.1%) of RET rearrangements. These findings support the notion of a good genotype/ phenotype correlation in PTC (Pierotti et al., 1996) , where specific molecular alterations are associated with specific tumor variants.
On the whole, our data demonstrate that BRAF and RET/TRK are deregulated with similar frequency in PTC, and that in one-third of the samples any associated genetic alteration remains to be determined. To assess whether the different PTC-associated genetic lesions observed could generate different and specific gene expression patterns, we performed an experiment with cDNA microarrays. A total number of 31 PTCs, including 11 samples carrying BRAF mutation (BRAF mutated), 10 carrying either RET or NTRK1 rearrangement (RTK rearranged), and 10 with unknown genetic lesion (unknown) were analysed using two microarrays spotted with a total of about 9000 cDNA clones. Unsupervised hierarchical clustering showed that PTCs do not group according to their genetic lesion. The dendrogram resulting from cluster analysis on the first array is shown in Figure 1a . Similar results were obtained by analysing the data using different filtering, normalization and hierarchical clustering procedures. On the whole our analysis showed no strong differences in global gene expression profiles of PTCs, outlining that, although triggered by different genetic lesions, the PTCs behave as a homogeneous group in terms of gene expression profiles. This evidence leads to the assumption that, most likely, the same pathway(s) is (are) involved in all the cases. It is worth noting that the same approach showed clear differences between PTCs and FTCs samples (our unpublished results). When the data were subjected to supervised analysis (class comparison), no significant differences were detected by comparing the PTC 'unknown' group to the 'RTK rearranged' or 'BRAF mutated' groups. Interestingly, however, the comparison between 'RTK rearranged' and 'BRAF mutated' PTC generated a list of 69 genes differentially expressed (Figure 1b and c) . These include several genes encoding proteins involved in signal transduction. Among these, proteins proposed to play a role in tumor invasion, angiogenesis and thyroid carcinogenesis, such as autotaxin and PKCe (Knauf et al., 2002; Kehlen et al., 2004) have been identified. These findings could suggest that although RTK and BRAF act along the same signal transduction pathway, their activity occur at different levels, leading to the regulation of different gene sets.
Our data and other studies support the notion that deregulation of either RTKs or BRAF occur in a high fraction of PTC. Both alterations lead to the activation of the common downstream MAP kinases pathway, which may be a target for pharmacological intervention in various neoplastic diseases. Despite such similarity, PTCs carrying BRAF mutation or Tumor samples: All PTCs were collected at the Department of Pathology at the Istituto Nazionale Tumori (Milan, Italy) from 1984 to date. Snap-frozen material was available in 55 cases. After the initial review and selection of cases (by P Collini), glass slides from all PTCs were re-examined, in a blinded manner, by two experienced pathologists (P Collini and S Pilotti), and subclassified as well as differentiated or tall cell variant PTCs. DNA isolation and sequencing: Genomic DNA from both paraffin-embedded and snap-frozen PTC specimens was isolated using the Qiagen Tissue Kit (Qiagen, Chatsworth, CA, USA) as described (Namba et al., 2003) . We analysed exons 11 and 15 of BRAF, the whole sequence of H-and K-Ras, and exon 2 of N-Ras through DNA amplification using specific primers (Namba et al., 2003; Davies et al., 2002) . The primers for BRAF analysis included the exonic sequence and at least 50 nucleotides of the flanking intronic sequences. Amplified products were purified by Qiamp Purification Kit (Qiagen) and then directly sequenced on an ABI PRISM 3100 automated capillary Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Analysis of RET and NTRK1 rearrangements: Total RNA was extracted from snap-frozen material according to standard protocols. cDNAs were synthesized with an oligo-dT primer and superscript reverse transcriptase (BRL, Bethesda, MD, USA) in duplicate and then amplified by PCR. Intron-spanning cDNA fragment of the housekeeping gene NCOA4 (895 bp) was amplified to ensure the appropriate quality of the RNA. Samples were analysed for the expression of the RET transmembrane (TM) and tyrosine kinase (TK) domains using primers reported previously (Klugbauer et al., 1995) . Samples expressing the RET TK domain were tested for the presence of the most frequent oncogenes, RET/PTC1-2-3, using the following primers: RET/PTC1 (5 0 -ATTGT CATCTCGCCGTTC-3 0 ; 5 0 -CCTGCTCTGCCTTTCAGATGGAA-3 0 ); RET/PTC2 (5 0 -GTGATTGATCAAGGAGAGACG-3 0 ; 5 0 -AGG GAATTCCCACTTTGGATC-3 0 ); and RET/PTC3 (5 0 -TGGAGAA GAGGAGCTGTATCT-3 0 ; 5 0 -AGGGAATTCCCACTTTGGATC-3 0 ). The presence of a specific RET oncogene was further confirmed by DNA sequencing. The samples expressing RET/PTC oncogenes were considered rearranged, those expressing both RET TM and TK domains and negative for any RET/PTC oncogene were considered expressing the wild-type RET receptor. To detect NTRK1 rearrangements, samples were first analysed for the expression of NTRK1 TK domain using the following primers: 5 0 -CCTCCGATCCCATG GACCCGA-3 0 ; 5 0 -AGCTTGCCGTAGGTGAAGAT-3 0 ). Positive samples were tested for the expression of the different oncogenes using the following primers:
. The presence of a specific TRK oncogene was further confirmed by DNA sequencing. PCR amplifications were performed using Taq polymerase (Applied Biosystems), 0.2 mM dNTPs and 0.2 mm of each primer. PCR products were visualized on 2% agarose gels stained with ethidium bromide multidimensional scaling of genes differentially expressed between BRAF mutated and RTK rearranged PTCs. Tumors carrying RTK rearrangement are green; the asterisks mark samples with NTRK1 rearrangement. Samples in red carry BRAF mutation; for cases in blue, none of the above genetic alterations was detected. Total RNA was extracted using Trizol (Life Technologies, Fredrick, MA, USA) and treated with DNase I (Qiagen, Valencia, CA, USA). RNAs were hybridized on cDNA microarrays using a common reference sample, consisting of a pool of 10 human cell lines from different tissues. Samples were labeled and hybridized as described (De Cecco et al., 2004) . Two different cDNA arrays, containing respectively, 4451 and 4272 unique clones, including genes selected from the Human sequence verified IMAGE clone collection (Research Genetics/Invitrogen, Carlsbad, CA, USA) and internal controls, and spotted in triplicate, were used. The data set were normalized using lowess smoother normalization (Yang et al., 2002) and then filtered by removing clones having more than 10% missing (invalid) values for cluster analysis (3906 clones for the first and 3710 clones for the second array). The Pearson's metric and average linkage methods were applied when performing hierarchical clustering using JExpress Pro (Molmine, Berger, Norway) (Dysvik and Jonassen, 2001 ). Supervised analysis (class comparison, clustering and multidimensional scaling) was performed using BRB-ArrayTools v3.1 (McShane et al., 2002) 
